

**Breaking the Wall of even the  
Toughest pathogens...**



Carrying the ultimate spectrum of

**4th** Generation  
**CEPHALOSPORIN**

# Dizma-4

500mg & 1G  
Injection

(Cefepime for injection USP)

For Intravenous or  
Intramuscular Use

4<sup>th</sup> Generation  
CEPHALOSPORIN



## Broad spectrum of Activity\*

Dizma-4 (Cefepime) a 4<sup>th</sup> generation cephalosporin has a broad spectrum of bactericidal activity against gram +ve and gram -ve bacteria, Dizma-4 (Cefepime) can be used as mono therapy prior to identification of causative organism

Dizma-4 - Gram-Negative Coverage		Gram-Positive Coverage
Acinetobacter spp.	Legionella spp.	Staphylococcus aureus
Aeromonas hydrophila	Morganella morganii	Staphylococcus epidermidis
Capnocytophaga spp.	Moraxella catarrhalis	S. hominis
Citrobacter spp.	Neisseria gonorrhoeae	S. saprophyticus
Campylobacter jejuni	Neisseria meningitidis	Streptococcus pyogenes (Group A streptococci)
Enterobacter spp.	Proteus spp	Streptococcus agalactiae (Group B streptococci)
E. coli	Pro viden cia	Streptococcus pneumoniae
Gardnerella vaginalis	Pseudomonas spp.	Group-C Beta-Haemolytic streptococci
Haemophilus ducreyi	Salmonella spp.	Group-G Beta-Haemolytic streptococci
Haemophilus influenzae	Serratia	Group-F Beta-Haemolytic streptococci
Haemophilus parainfluenzae	Shigella spp.	
Hafnia alvei	Yersinia enterocolitica	
Klebsiella spp.		

	Severity of Infections	Dose, frequency and route of administration
<b>Adults:</b>	Mild to moderate infections	1G q 12 h IV or IM
	Severe infections	2G IV 12 h
<b>Paediatrics:</b>	(Age > 2 months with body weight <40kg)	50 mg/kg q 12h
	Age 1-2 months	30mg / kg q 12 h

- **DIZMA-4** is reserved to treat moderate to severe nosocomial pneumonia
- **DIZMA-4** is empiric choice in treatment of febrile neutropenia
- **DIZMA-4** as empiric therapy for intra abdominal infections\*<sup>3</sup>
- **DIZMA-4** has broad spectrum of activity
- **DIZMA-4** is resistant to hydrolysis by most beta-lactamases
- **DIZMA-4** has low resistance potential and good susceptibility<sup>4,6</sup>
- **DIZMA-4** has convenient BID dosage

### Brief Product Information:

**Active ingredients:** Cefepime hydrochloride. **Indications:** Lower respiratory tract infections, Urinary tract infections including Pyelonephritis, Skin and skin structure infections, Intra-abdominal infections, Gynecologic infections, Septicemia, Empiric therapy for febrile neutropenic patient, Bacterial meningitis caused by susceptible bacteria. **Dose and administration:** The recommended dosage schedule for adults and pediatric patients > 40 kg with normal renal function is 0.5 to 1gm IM or IV 12 hourly in mild to moderate urinary tract infections (UTI), in mild to moderate other than UTI: 1gm IM or IV 12 hourly. In severe infections 2gm IV 12 hourly and in very severe or life-threatening infections 2gm IV 8 hourly. In patients 1-2 months of age 30mg/kg 12h or 8h. The usual recommended dosage schedule in Pneumonia, urinary tract infections, and skin and skin structure infections in pediatric patients > 2 months of age with body weight <40kg is 50mg/kg 12h or 8h, in patients <2 months of age 30mg/kg 12h or 8h. For more severe infections like Septicemia, bacterial meningitis, and empiric treatment of febrile neutropenia 50mg/kg 8h for 7-10 days. A dosage schedule of q8h can be used. **Surgical Prophylaxis:** In patients undergoing intra-abdominal surgery, a single 2g IV dose of Dizma-4 starting 60 minutes before initial surgical incision followed by metronidazole IV. For IM administration, Dizma-4 500mg vial should be constituted with 1.5ml sterile water for injection and gm with 3.0ml sterile water for injection. For direct IV administration, Dizma-4 500mg vial should be constituted with 5ml sterile water for injection and 1gm with 10ml sterile water for injection. The solution to be injected directly into the vein over period of 3 to 5 minutes. IV infusion to be infused in 30min with sterile diluent. **Contraindications:** Known hypersensitivity to Cefepime and the cephalosporin class of antibiotics, penicillins or other beta-lactam antibiotics. **Warnings and precautions:** Clostridium difficile associated diarrhea (CDAD), impaired renal function, Pregnancy & lactation. Prolonged use may result in overgrowth of non-susceptible organisms. **Adverse reactions:** Rash, pruritus, urticaria, nausea, vomiting, unspecified morbillias, diarrhoea, colitis, headache, fever, vaginitis, erythema, abdominal pain, constipation, vasodilation, dyspnea, dizziness, paresthesia, genital pruritis, taste perversion, chills, phlebitis and inflammation, positive Coombs's test and transient elevations in SGOT, serum creatinine and BUN. M.R.P. Dizma-4 inj. 500mg 1's (vial) Rs. 300.00 and Dizma-4 inj. 1 gm 1's (Vial) Rs. 600.00.

**References:** 3. Solomkin JS et al. "Diagnosis and Management of Complicated Intra-Abdominal Infection in Adults and Children: Guidelines by the surgical infection society and the Infectious Diseases Society of America." SURGICAL INFECTIONS Volume 11, Number 1, 2010. 4. Hoban DJ et al. "Susceptibility of Gram-Negative Pathogens Isolated from Patients with Complicated Intra-Abdominal Infections in the United States, 2007-2008: Results of the Study for Monitoring Antimicrobial Resistance Trends (SMART) ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, July 2010, p. 3031-3034. Vol. 54, No. 7. 6. K.F. Bodmann, "Current Guidelines for the treatment of severe pneumonia and sepsis", Chemotherapy 2005;51:227-233. \* In combination with metronidazole



**Zafa Pharmaceutical Laboratories (Pvt.) Ltd.**  
L-1/B, Block-22, FEDERAL 'B' INDUSTRIAL AREA, KARACHI-7550 (PAKISTAN)  
Email: zafaph@cyber.net.pk, Website: www.zafa.com.pk

